STAT

Despite modest gains, Trump basks in recognition for Washington’s response to the opioid crisis

President Trump basked in applause at a signing ceremony for an opioids bill today. Is the legislation worth the celebration?
President Donald Trump stands with business leaders on the stage during an East Room event at the White House.

WASHINGTON — The claps died down for a moment, but quickly came back louder than before: by the end, the assembled lawmakers, Cabinet members, law enforcement officials, and White House staff applauded President Trump and his efforts to address the opioid crisis for nearly 40 seconds.

It was a lengthy victory lap for a year of modest progress combating the opioid crisis, culminating in the president signing a sweeping but largely unambitious bill.

“Together, we are going to end the

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks